PAVmed Inc (PAVM)
NASDAQ:PAVM
Want to see PAVM full AI Analyst Report?
PAVM Stock Chart & Stats
$7.75
$0.11(1.44%)
At close: 4:00 PM EST
$7.75
$0.11(1.44%)
Day’s Range― - ―
52-Week Range$5.45 - $28.44
Previous Close$8
Volume99.04K
Average Volume (3M)377.79K
Market Cap
$41.77M
Enterprise Value$13.88M
Total Cash (Recent Filing)$6.46M
Total Debt (Recent Filing)$17.01M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Aug 18, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-37.69
Shares Outstanding7,159,034
10 Day Avg. Volume774,204
30 Day Avg. Volume377,786
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)0.13
Price to Sales (P/S)62.51
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.33
Enterprise Value/Revenue163.28
Enterprise Value/Gross Profit-60.08
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$40.50Price Target Upside422.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.14
Revenue Forecast (FY)$480.00K
Bulls Say, Bears Say
Bulls Say
Recapitalization And Simplified Cap TableThe multi-step recapitalization retired prior convertibles and simplified equity, creating structural financing flexibility. This durable improvement reduces immediate refinancing pressure, clarifies governance, and makes it easier to fund subsidiaries or transact assets without legacy conversion overhang.
Equity Stake In Lucid With Extended RunwayA meaningful Lucid stake and $36M equity-method balance tie PAVmed to a growing diagnostics business with federal/VA contracts and payer engagement. That asset exposure and management-fee potential provide a durable non‑operating value stream and diversified upside beyond direct device sales.
Veris Commercial Rollout And Device DevelopmentVeris’ EHR integration and institutional rollout create a reproducible commercial pathway with clinical data from a large registry. Progress toward an implantable physiologic monitor and regulatory submission planning supports multi‑year product commercialization and recurring clinical adoption potential.
Bears Say
Negative And Unstable Cash FlowOperating and free cash flow are negative across reported periods and TTM shows very large cash burn. The core business does not generate sustainable internal funding, creating a durable dependence on external capital which limits organic scaling and increases dilution risk over time.
Stressed And Volatile Balance SheetHistorical negative equity and dramatic leverage swings—particularly the high debt-to-equity in 2025—indicate a stressed capital structure. Even with recent improvements, this volatility raises persistent refinancing and dilution risk and complicates long‑term capital planning and investor confidence.
Reliance On Milestone-contingent FinancingWith only $6.5M cash and material upside tied to warrant exercises contingent on regulatory/payer milestones, near‑term liquidity and growth hinge on external events. This structural reliance heightens execution risk and could delay commercialization if coverage or FDA timelines slip.
PAVmed News
PAVM FAQ
What was PAVmed Inc’s price range in the past 12 months?
PAVmed Inc lowest stock price was $5.45 and its highest was $28.44 in the past 12 months.
What is PAVmed Inc’s market cap?
PAVmed Inc’s market cap is $41.77M.
When is PAVmed Inc’s upcoming earnings report date?
PAVmed Inc’s upcoming earnings report date is Aug 18, 2026 which is in 74 days.
How were PAVmed Inc’s earnings last quarter?
PAVmed Inc released its earnings results on May 15, 2026. The company reported -$4.42 earnings per share for the quarter, missing the consensus estimate of -$0.7 by -$3.72.
Is PAVmed Inc overvalued?
According to Wall Street analysts PAVmed Inc’s price is currently Undervalued.
Does PAVmed Inc pay dividends?
PAVmed Inc does not currently pay dividends.
What is PAVmed Inc’s EPS estimate?
PAVmed Inc’s EPS estimate is -0.47.
How many shares outstanding does PAVmed Inc have?
PAVmed Inc has 7,159,034 shares outstanding.
What happened to PAVmed Inc’s price movement after its last earnings report?
PAVmed Inc reported an EPS of -$4.42 in its last earnings report, missing expectations of -$0.7. Following the earnings report the stock price went up 1.24%.
Which hedge fund is a major shareholder of PAVmed Inc?
Currently, no hedge funds are holding shares in PAVM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PAVmed Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.50 (422.58% Upside)
$40.50 (422.58% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 7.8%
Last 30 Days ▼ 7.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.77%
12-Months-Change
Fundamentals
Return on Equity
-9999.00%
Trailing 12-Months
Asset Growth
-14.02%
Trailing 12-Months
Company Description
PAVmed Inc
PAVmed Inc. is a medical technology company focused on the development and commercialization of innovative medical devices and diagnostic tools. Operating primarily in the healthcare sector, PAVmed aims to improve patient outcomes through its core products, which include devices for gastroenterology, urology, and other specialty areas. The company is known for its commitment to addressing unmet medical needs with solutions that enhance clinical workflows and patient care.
PAVM Company Deck
PAVM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized successful capitalization/recapitalization steps, a cleaned cap table, active commercial progress at Lucid and Veris (EHR integration live, VA orders, positive payer engagement), relaunch of the device portfolio with experienced leadership, and measured technical progress on the implantable monitor. At the same time, liquidity remains constrained ($6.5M cash) and a number of positive outcomes depend on milestone-triggered financings (warrants, FDA clearance, Medicare LCD). GAAP results were volatile due to mark-to-market accounting and preferred dividends materially impacted reported earnings; operating expenses have risen ~23% vs. recent quarterly averages. Overall, positives (strategic restructuring, multiple operational milestones, extended Lucid runway, and product development progress) outweigh the near-term financial and milestone risks, but execution and milestone realization will be critical.View all PAVM earnings summariesPAVM Stock 12 Month Forecast
Average Price Target
$40.50
▲(422.58% Upside)
Technical Analysis
Strata Skin Sciences
―
Biomerica
―
Co-Diagnostics
―
Tenon Medical, Inc.
―
Heart Test Laboratories, Inc.
―
Ownership Overview
13.42% Insiders
0.30% Mutual Funds
6.78% Other Institutional Investors
79.42% Public Companies and
Individual Investors